Deranged energy substrate metabolism in the failing heart

Current Hypertension Reports

Volumn 8, Issue 6, 2006, Pages 465-471

  Tian, Qi ^b   Barger, Philip M ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ACETYL COENZYME A; ADENOSINE DIPHOSPHATE; ADENOSINE TRIPHOSPHATE; FATTY ACID; FLAVINE ADENINE NUCLEOTIDE; INSULIN; NICOTINAMIDE ADENINE DINUCLEOTIDE; OXYGEN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE; TRANSCRIPTION FACTOR;

BIOSYNTHESIS; DIABETES MELLITUS; DISEASE EXACERBATION; DRUG TARGETING; ENERGY METABOLISM; FATTY ACID OXIDATION; GENE TARGETING; GENETIC TRANSCRIPTION; HEART FAILURE; HEART PERFORMANCE; HEART PROTECTION; HEART VENTRICLE HYPERTROPHY; HUMAN; INSULIN RESISTANCE; NONHUMAN; OXYGEN CONSUMPTION; PERIPHERAL EDEMA; PROTEIN FUNCTION; REVIEW; SIGNAL TRANSDUCTION;

ACYL COENZYME A; ADENOSINE TRIPHOSPHATE; ANIMALS; DOWN-REGULATION; ENERGY METABOLISM; HEART FAILURE, CONGESTIVE; HUMANS; LIPIDS; MYOCARDIUM; PPAR GAMMA; TRANS-ACTIVATION (GENETICS);

EID: 33751569364     PISSN: 15226417     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11906-006-0024-9     Document Type: Review

References (47)

1. Taegtmeyer H, Golfman L, Sharma S, et al.: Linking gene expression to function: metabolic flexibility in the normal and diseased heart. Ann N Y Acad Sci 2004, 1015:202-213.
2. Champe PC, Harvey RA, eds: Biochemistry, edn 2. Philadelphia: Lippincott Raven; 1994.
3. Paolisso G, Gambardella A, Galzerano D, et al.: Total-body and myocardial substrate oxidation in congestive heart failure. Metabolism 1994, 43:174-179.
4. Taylor M, Wallhaus TR, Degrado TR, et al.: An evaluation of myocardial fatty acid and glucose uptake using PET with [18F]fluoro-6-thia-heptadecanoic acid and [18F]FDG in patients with congestive heart failure. J Nucl Med 2001, 42:55-62.
5. Davila-Roman VG, Vedala G, Herrero P, et al.: Altered myocardial fatty acid and glucose metabolism in idiopathic dilated cardiomyopathy. J Am Coll Cardiol 2002, 40:271-277.
6. Chandler MP, Kerner J, Huang H, et al.: Moderate severity heart failure does not involve a downregulation of myocardial fatty acid oxidation. Am J Physiol Heart Circ Physiol 2004, 287:H1538-H1543.
7. Sack MN, Rader TA, Park S, et al.: Fatty acid oxidation enzyme gene expression is downregulated in the failing heart. Circulation 1996, 94:2837-2842.
8. Sack MN, Disch DL, Rockman HA, Kelly DP: A role for Sp and nuclear receptor transcription factors in a cardiac hypertrophic growth program. Proc Natl A cad Sci U S A 1997, 94:6438-6443.
9. Barger PM, Brandt JM, Leone TC, et al.: Deactivation of peroxisome proliferator-activated receptor-alpha during cardiac hypertrophic growth. J Clin Invest 2000, 105:1723-1730.
10. Razeghi P, Young ME, Alcorn JL, et al.: Metabolic gene expression in fetal and failing human heart. Circulation 2001, 104:2923-2931.
11. Desvergne B, Wahli W: Peroxisome proliferator-activated receptors: nuclear control of metabolism. Endocr Rev 1999, 20:649-688.
12. Lehman JJ, Barger PM, Kovacs A, et al.: Peroxisome proliferator-activated receptor gamma coactivator-1 promotes cardiac mitochondrial biogenesis. J Clin Invest 2000, 106:847-856.
13. Motojima K, Passilly P, Peters JM, et al.: Expression of putative fatty acid transporter genes are regulated by peroxisome proliferator-activated receptor alpha and gamma activators in a tissue- and inducer-specific manner. J Biol Chem 1998, 273:16710-16714.
14. van der Lee KA, Vork MM, De Vries JE, et al.: Long-chain fatty acid-induced changes in gene expression in neonatal cardiac myocytes. J Lipid Res 2000, 41:41-47.
15. Djouadi F, Weinheimer CJ, Saffitz JE, et al.: A gender-related defect in lipid metabolism and glucose homeostasis in peroxisome proliferator-activated receptor alpha-deficient mice. J Clin Invest 1998, 102:1083-1091.
16. Djouadi F, Brandt JM, Weinheimer CJ, et al.: The role of the peroxisome proliferator-activated receptor alpha (PPAR alpha) in the control of cardiac lipid metabolism. Prostaglandins Leukot Essent Fatty Acids 1999, 60:339-343.
17. Young ME, Goodwin GW, Ying J, et al.: Regulation of cardiac and skeletal muscle malonyl-CoA decarboxylase by fatty acids. Am J Physiol Endocrinol Metab 2001, 280: E471-E479.
18. Campbell FM, Kozak R, Wagner A, et al.: A role for peroxisome proliferator-activated receptor alpha (PPARalpha) in the control of cardiac malonyl-CoA levels: reduced fatty acid oxidation rates and increased glucose oxidation rates in the hearts of mice lacking PPARalpha are associated with higher concentrations of malonyl-CoA and reduced expression of malonyl-CoA decarboxylase. J Biol Chem 2002, 277:4098-4103.
19. 2-dependent modulation of mitochondrial fatty acid oxidation. J Biol Chem 2001, 276:27605-27612.
20. Razeghi P, Young ME, Abbasi S, Taegtmeyer H: Hypoxia in vivo decreases peroxisome proliferator-activated receptor alpha-regulated gene expression in rat heart. Biochem Biophys Res Commun 2001, 287:5-10.
21. Ballal K, Sekiguchi K, Sarmishtha N, Barger P: ERK MAPK regulation of cardiac X receptor is involved in impaired fatty acid beta-oxidation during hypertrophic growth [abstract]. Circulation 2004, 110(suppl):946.
22. Entman ML, Bornet EP, Van Winkle WB, et al.: Association of glycogenolysis with cardiac sarcoplasmic reticulum: II. Effect of glycogen depletion, deoxycholate solubilization and cardiac ischemia: evidence for a phorphorylase kinase membrane complex. J Mol Cell Cardiol 1977, 9:515-528.
23. Stanley WC, Recchia FA, Lopaschuk GD: Myocardial substrate metabolism in the normal and failing heart. Physiol Rev 2005, 85:1093-1129.
24. Dewald O, Sharma S, Adrogue J, et al.: Downregulation of peroxisome proliferator-activated receptor-alpha gene expression in a mouse model of ischemic cardiomyopathy is dependent on reactive oxygen species and prevents lipotoxicity. Circulation 2005, 112:407-415.
25. Young ME, Laws FA, Goodwin GW, Taegtmeyer H: Reactivation of peroxisome proliferator-activated receptor alpha is associated with contractile dysfunction in hypertrophied rat heart. J Biol Chem 2001, 276:44390-44395.
26. Panagia M, Gibbons GF, Radda GK, Clarke K: PPAR-alpha activation required for decreased glucose uptake and increased susceptibility to injury during ischemia. Am J Physiol Heart Circ Physiol 2005, 288:H2677-H2683.
27. Finck BN, Lehman JJ, Leone TC, et al.: The cardiac phenotype induced by PPARalpha overexpression mimics that caused by diabetes mellitus. J Clin Invest 2002, 109:121-130.
28. Sambandam N, Morabito D, Wagg C, et al.: Chronic activation of PPARalpha is detrimental to cardiac recovery after ischemia. Am J Physiol Heart Circ Physiol 2006,290:H87-H95.
29. Ogata T, Miyauchi T, Sakai S, et al.: Stimulation of peroxisome-proliferator-activated receptor alpha (PPAR alpha) attenuates cardiac fibrosis and endothelin-1 production in pressure-overloaded rat hearts. Clin Sci (Lond) 2002, 103(suppl 48):284S-288S
30. Luptak I, Balschi JA, Xing Y, et al.: Decreased contractile and metabolic reserve in peroxisome proliferator-activated receptor-alpha-null hearts can be rescued by increasing glucose transport and utilization. Circulation 2005, 112:2339-2346.
31. Loichot C, Jesel L, Tesse A, et al.: Deletion of peroxisome proliferators-activated receptor-alpha induces an alteration of cardiac functions. Am J Physiol Heart Circ Physiol 2006, 291:H161-166.
32. Yue TL, Bao W, Jucker BM, et al.: Activation of peroxisome proliferator-activated receptor-alpha protects the heart from ischemia/ reperfusion injury. Circulation 2003, 108:2393-2399.
33. Tabernero A, Schoonjans K, Jesel L, et al.: Activation of the peroxisome proliferator-activated receptor alpha protects against myocardial ischaemic injury and improves endothelial vasodilatation. BMC Pharmacol 2002, 2:10.
34. Tian Q, Barger PM: Do PPARs play a role in cardiac hypertrophy and heart failure? Drug Discov Today: Disease Mechanism 2005, 2:109-114.
35. Cheng L, Ding G, Qin J, et al.: Peroxisome proliferator-activated receptor delta activates fatty acid oxidation in cultured neonatal and adult cardiomyocytes. Biochem Biophys Res Commun 2004, 313:277-286.
36. Cheng L, Ding G, Qin Q, et al.: Cardiomyocyte-restricted peroxisome proliferator-activated receptor-delta deletion perturbs myocardial fatty acid oxidation and leads to cardiomyopathy. Nat Med 2004, 10:1245-1250.
37. Patel C, Wyne KL, McGuire DK: Thiazolidinediones, peripheral oedema and congestive heart failure: what is the evidence? Diab Vasc Dis Res 2005, 2:61-66.
38. Wu L, Wang R, De Champlain J, Wilson TW: Beneficial and deleterious effects of rosiglitazone on hypertension development in spontaneously hypertensive rats. Am J Hypertens 2004, 17:749-756.
39. Mehrabi MR, Haslmayer P, Humpeler S, et al.: Quantitative analysis of peroxisome proliferator-activated receptor gamma (PPARgamma) expression in arteries and hearts of patients with ischaemic or dilated cardiomyopathy. Eur J Heart Fail 2003, 5:733-739.
40. Yamamoto K, Ohki R, Lee RT, et al.: Peroxisome proliferator-activated receptor gamma activators inhibit cardiac hypertrophy in cardiac myocytes. Circulation 2001, 104:1670-1675.
41. Asakawa M, Takano H, Nagai T, et al.: Peroxisome proliferator-activated receptor gamma plays a critical role in inhibition of cardiac hypertrophy in vitro and in vivo. Circulation 2002, 105:1240-1246.
42. Duan SZ, Ivashchenko CY, Russell MW, et al.: Cardiomyocyte-specific knockout and agonist of peroxisome proliferator-activated receptor-gamma both induce cardiac hypertrophy in mice. Circ Res 2005, 97:372-379.
43. Sharma S, Adrogue JV, Golfman L, et al.: Intramyocardial lipid accumulation in the failing human heart resembles the lipotoxic rat heart. FASEB J 2004, 18:1692-1700.
44. Listenberger LL, Han X, Lewis SE, et al.: Triglyceride accumulation protects against fatty acid-induced lipotoxicity. Proc Natl Acad Sci U S A 2003, 100:3077-3082.
45. Shimabukuro M, Zhou YT, Levi M, Unger RH: Fatty acid-induced beta cell apoptosis: a link between obesity and diabetes. Proc Natl Acad Sci U S A 1998, 95:2498-2502.
46. McGarry JD: Banting lecture 2001: dysregulation of fatty acid metabolism in the etiology of type 2 diabetes. Diabetes 2002,51:7-18.
47. Leone TC, Weinheimer CJ, Kelly DP: A critical role for the peroxisome proliferator-activated receptor alpha (PPARalpha) in the cellular fasting response: the PPARalpha-null mouse as a model of fatty acid oxidation disorders. Proc Natl Acad Sci USA 1999, 96:7473-7478.